Retcam fluorescein angiography findings in eyes with advanced retinoblastoma

Kim, Jonathan W.; L, Ngai; Sadda, Srinivas R; Murakami, Yohko; Lee, Diana K; Murphree, A. Linn

doi:10.1136/bjophthalmol-2014-305180

Cited by 34 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(i) At presentation, to detect subclinical iris neovascularization (Kim et al, 2014) and assess the tumoral and retinal vascularization status (Ohnishi et al, 1982).…”

Section: Fundus Documentation and Fluorescein Angiographymentioning

confidence: 99%

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Munier

Beck‐Popovic

Chantada

et al. 2019

Progress in Retinal and Eye Research

160

157

View full text Add to dashboard Cite

Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a "state of metastatic grace" never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the "state of metastatic grace", with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.

show abstract

“…(i) At presentation, to detect subclinical iris neovascularization (Kim et al, 2014) and assess the tumoral and retinal vascularization status (Ohnishi et al, 1982).…”

Section: Fundus Documentation and Fluorescein Angiographymentioning

confidence: 99%

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Munier

Beck‐Popovic

Chantada

et al. 2019

Progress in Retinal and Eye Research

160

157

View full text Add to dashboard Cite

show abstract

“…Firstly, subclinical neovascularization of the iris (NVI) can be distinguished using Retcam FA. In a recent study, eyes with advanced retinoblastoma, NVI was documented appearing as placoid or patchy areas of hyper fluorescence involving one or more sectors of the iris [19]. This finding typically occurred between 1 and 2 min.…”

Section: Fluorescein Angiographymentioning

confidence: 98%

Retinoblastoma: Presentation, Evaluation, and Diagnosis

Langevin¹,

Marr²

2019

Retinoblastoma - Past, Present and Future

View full text Add to dashboard Cite

Retinoblastoma was initially described in a case series by Dr. James Wardrop in 1809. Since then, the evaluation and diagnosis of retinoblastoma has progressed significantly, thus providing a framework for successful therapy with up to 97% survival rate in developed nations. Here we outline the presentation, evaluation, and detailed diagnostic steps of any child presenting with signs and symptoms of retinoblastoma (RB). We detail the questions and pertinent history to obtain, describe in detail the examination under anesthesia, ancillary testing, and recommendations for both anesthesia and neuroimaging. We also cover the differential diagnosis of retinoblastoma and the most common simulating lesions to present to an ophthalmologist. We describe the ways to determine if a patient has retinoblastoma or some simulating lesion, and the characteristics associated with each possibility. Finally, we briefly address genetic counseling and the next steps after diagnosis.

show abstract

“…Key imaging features that this technique may highlight include iris neovascularization, dilated tumor-associated retinal vessels, intrinsic tumor vasculature, venous leakage, and microvasculature changes. 5 Compared with completely perfused tumors, partially perfused tumors may require fewer cycles of intra-arterial chemotherapy (IAC) to achieve regression. 6 Fluorescein angiography can also detect treatment-related ischemic side effects.…”

Section: Fluorescein Angiographymentioning

confidence: 99%

Retinoblastoma: What the Neuroradiologist Needs to Know

Silvera¹,

Guerin²,

Brinjikji³

et al. 2021

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

Retinoblastoma is the most common primary intraocular tumor of childhood. Accurate diagnosis at an early stage is important to maximize patient survival, globe salvage, and visual acuity. Management of retinoblastoma is individualized based on the presenting clinical and imaging features of the tumor, and a multidisciplinary team is required to optimize patient outcomes. The neuroradiologist is a key member of the retinoblastoma care team and should be familiar with characteristic diagnostic and prognostic imaging features of this disease. Furthermore, with the adoption of intra-arterial chemotherapy as a standard of care option for globe salvage therapy in many centers, the interventional neuroradiologist may play an active role in retinoblastoma treatment. In this review, we discuss the clinical presentation of retinoblastoma, ophthalmic imaging modalities, neuroradiology imaging features, and current treatment options. ABBREVIATIONS: IACR etinoblastoma is the most common primary intraocular malignancy in children. Prompt diagnosis is essential to preserving life, eye, and sight. Neuroradiologists play an important role in diagnosis, staging, and treatment of patients with retinoblastoma. In this review, we aim to educate neuroradiologists regarding retinoblastoma imaging features and basic principles of treatment. EPIDEMIOLOGYRetinoblastoma affects 1 in 16,000 births, 1 with 8000-10,000 children diagnosed annually. There are no known geographic, racial, or sex predilections. Heritable retinoblastoma is diagnosed at a median age of 12 months and nonheritable disease at 24 months, with 80% diagnosed before 4 years of age. CLINICAL PRESENTATION AND DIAGNOSISRetinoblastoma is diagnosed by physical examination and classified as International Classification of Retinoblastoma groups A through E according to increasing severity. The most common

show abstract

Retcam fluorescein angiography findings in eyes with advanced retinoblastoma

Cited by 34 publications

References 16 publications

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Retinoblastoma: Presentation, Evaluation, and Diagnosis

Retinoblastoma: What the Neuroradiologist Needs to Know

Contact Info

Product

Resources

About